Go Deep
Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,983 | -2.1 | 1.92 | 0.01 | 355.22 |
| Oct 2026 | 21,008 | -2.1 | 1.90 | 0.01 | 351.31 |
| Oct 2026 | 21,099 | -2.1 | 1.85 | 0.01 | 340.91 |
| Oct 2026 | 21,290 | -1.9 | 1.73 | 0.01 | 318.24 |
| Oct 2026 | 21,165 | -2.0 | 1.80 | 0.01 | 332.81 |
| Oct 2026 | 20,925 | -2.2 | 1.95 | 0.01 | 360.30 |
| Oct 2026 | 20,867 | -2.2 | 1.99 | 0.01 | 366.03 |
| Oct 2026 | 20,808 | -2.3 | 2.03 | 0.01 | 371.90 |
Unicycive Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -1,722,000.0 | -12,823,000.0 | -14,668,000.0 | -6,011,000.0 |
| EPS | -0.1 | -0.5 | — | -0.3 |
Unicycive Therapeutics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 675,000.0 | 951,000.0 | — |
| Net Profit | -26,555,000.0 | -36,729,000.0 | -30,544,000.0 | -18,058,000.0 | — |
| EPS | -1.7 | -5.7 | -12.8 | -12.0 | — |
Unicycive Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 49,135,000.0 | 31,668,000.0 | 14,191,000.0 | 2,818,000.0 | — |
| Total Liabilities | 18,938,000.0 | 24,237,000.0 | 18,000,000.0 | 3,284,000.0 | — |
| Total Equity | 30,197,000.0 | 7,431,000.0 | -3,809,000.0 | -466,000.0 | — |
Owes vs Owns
Unicycive Therapeutics, Inc. owed $0.26 for every $1 it owned in Jun 2026, down from $1.17 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.26× | 0.39× | 0.77× | 1.27× | 1.17× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Unicycive Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 84.0%Other assets 15.7%
How it's funded — Dec 2025
Payables 0.6%Other liabilities 37.8%Shareholders' equity 61.5%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 41.3 | 26.1 | 9.7 | 0.5 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.2 | 0.7 | 0.8 | 0.2 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 7.7 | 4.8 | 3.7 | 2.2 |
| Liabilities & equity | ||||
| Short-term debt | 0.1 | 0.1 | 0.0 | 0.0 |
| Long-term debt | 0.0 | 0.1 | 0.5 | 0.0 |
| Payables | 0.3 | 1.0 | 0.8 | 0.8 |
| Other liabilities | 18.6 | 23.1 | 16.7 | 2.4 |
| Shareholders' equity | 30.2 | 7.4 | -3.8 | -0.5 |
| Net tangible assets | 30.2 | 7.4 | -3.8 | -0.5 |
Unicycive Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -31,317,000.0 | -28,575,000.0 | -18,283,000.0 | -15,651,000.0 | — |
| Investing Activities | -12,095,000.0 | -72,000.0 | -12,000.0 | -2,000.0 | — |
| Financing Activities | 46,468,000.0 | 45,088,000.0 | 27,541,000.0 | -471,000.0 | — |